Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians

Pharmacogenetics

Volumn 7, Issue 3, 1997, Pages 187-191

  McLellan, Roman A ^a   Oscarson, Mikael ^a   Seidegård, Janeric ^b   Price Evans, David A ^c   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c The General Directorate of Armed Forces Health Services   (Saudi Arabia)

Author keywords

CYP2D locus; Cytochrome P450; Gene duplication; Saudi Arabia

Indexed keywords

CYTOCHROME P450 ISOENZYME;

ARTICLE; GENE DUPLICATION; GENE LOCUS; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SAUDI ARABIA;

ADULT; CYTOCHROME P-450 CYP2D6; DEOXYRIBONUCLEASE ECORI; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIGENE FAMILY; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SAUDI ARABIA;

EID: 0030811291     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199706000-00003     Document Type: Article

References (32)

1. Agúndez JAG, Martínez C, Ledesma MC, Ladona MG, Ladero JM, Benítez J. Genetic basis for differences in debrisoquine polymorphism between a Spanish and other white populations. Clin Pharmacol Ther 1994: 55, 412-417.
2. Agúndez JAG, Ledesma MC, Ladero JM, Benítez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995: 57, 265-269.
3. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996: 278, 441-446.
4. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990: 39, 533-537.
5. Armstrong M, Fairbrother K, Idle JR, Daly AK. The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics 1994: 4, 73-81.
6. Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nordin C. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985: 7, 478-480.
7. Bertilsson L, Dahl M-L, Sjöqvist F, Aberg-Wistedt A, Humble M, Johansson I, Lundqvist E, Ingelman-Sundberg M. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993: 341, 63.
8. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/Sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991: 10, 545-558.
9. Cavalli-Sforza LL, Piazza A, Menozzi P, Mountain J. Reconstruction of human evolution: Bringing together genetic, archaeological, and linguistic data. Proc Natl Acad Sci USA 1988: 85, 6002-6006.
10. Dahl M-L, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995: 274, 516-520.
11. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996: 6, 193-201.
12. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects. In: Kalow W, ed. Pharmacogenetics of Drug metabolism. New York: Pergamon Press, 1992: 625-648.
13. Evans DAP. Genetic factors in drug therapy. Cambridge: Cambridge University Press, 1993: Chapter 7.
14. Evans DAP, Krahn P, Narayanan N. The mephenytoin (cytochrome P450 2C19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. Pharmacogenetics 1995: 5, 64-71.
15. Evans DAP, Seidegärd J, Narayanan N. The GSTM1 genetic polymorphism in healthy Saudi Arabians and Filipinos, and Saudi Arabians with coronary atherosclerosis. Pharmacogenetics 1996: 6, 365-367.
16. Fonne-Pfister R, Meyer UA. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism. Biochem Pharmacol 1988: 37, 3829-3835.
17. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991: 48, 943-950.
18. 450, CYP2D locus. Nature 1990: 347, 773-776.
19. Heim MH, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990: 336, 529-532.
20. Heim MH, Meyer UA. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 1992: 14, 49-58.
21. Irshaid YM, Al-Hadidi HF, Rawashdeh NM. Dextromethorphan O-demethylation polymorphism in Jordanians. Eur J Clin Pharmacol 1993: 45, 271-273.
22. Islam SI, Idle JR, Smith RL. The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population. Xenobiotica 1980: 10, 819-825.
23. Johansson I, Yue Q-Y, Dahl M-L, Heim M, Säwe J, Bertilsson L, Meyer UA, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 1991: 40, 553-556.
24. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993: 90, 11825-11829.
25. Johansson I, Oscarson M, Yue Q-Y, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994: 46, 452-459.
26. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. J Biol Chem 1990: 265, 17209-17214.
27. Kalow W, Bertilsson L. Interethnic factors affecting drug response. Adv Drug Res 1994: 25, 1-53.
28. Mahgoub A, Idle JR, Smith RL. A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians. Xenobiotica 1979: 9, 51-56.
29. Masimirembwa CM, Johansson I, Hasler JA, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 CYP2D6 in a Zimbabwean population. Pharmacogenetics 1993: 3, 275-280.
30. Masimirembwa CM, Hasler JA, Bertilsson L, Johansson I, Ekberg O, Ingelman-Sundberg M. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin Pharmacol 1996a: 51, 117-122.
31. Masimirembwa CM, Persson I, Bertilsson L, Hasler JA, Ingelman-Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996b: 42, 713-719.
32. Wang S-L, Huang J-D, Lai M-D, Liu B-H, Lai M-L. Molecular basis of genetic variation in debrisoquine hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993: 53, 410-418.